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Methods: We assessed the expression patterns of CRBP-1 in 84 stage 
I non-small cell lung cancer (NSCLC), with the aim of characterizing 
their interrelationship via immunohistochemical staining (IHC) and 
survival. 
Figure 1. Expression of CRBP-1 in normal epithelial and alveolar cells
A, B, C- negative, D.focal positive. 
Figure 2. Expression of CRBP-1 in stage I non-small cell lung cancer cells, A and 
B- negative in adenoca and squamous cell ca, C and D- positive in adenoca 
and squamous cell ca. 
Results: The patients consisted of 65 men and 19 women. The mean 
age of these patients was 62 ± 10 years and 60 (71%) were smokers. 
Histologic subtypes included 40 cases of adenocarcinoma, 40 of squa-
mous cell carcinoma, and 4 of large cell carcinoma. Fourteen out of 84 
(16.7%) cases exhibited positive expression of CRBP-1 in more than 
25% of tumor cells. The sex, smoking status, tumor size, histologic 
types, and differentiation were not statistically different in the presence 
of CRBP-1 expression. In Kaplan-Meier survival analysis, expression 
of CRBP-1 proved to be a statistically signiﬁcant poor prognosis factor 
in overall survival (p=0.026). Cox regression analysis showed that the 
expression of CRBP-1 seemed to be associated with poor prognosis 
factor in stage I NSCLC (p=0.006).
Conclusions: CRBP-1 expression may play a partly role in carcino-
genesis and prognosis of early stage lung cancer. Further prospective 
studies are warranted to determine the molecular mechanism in regard 
to the role of CRBP-1 in lung carcinogenesis.
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Background: Vascular Endothelial Growth Factor (VEGF) is known to 
play an important role in angiogenic process of lung cancers. Whether 
the level of VEGF expression in cancers will reﬂect the response of 
Anti-VEGF treatment, no one know. We seek to answer two questions:
1) Can VEGF protein expression predict the lung cancer response from 
Anti-VEGF treatment? 
2)  Can Sequence Variation and Mutations of VEGF gene predict the 
tumor response In NSCLC lung cancer treatment?
Methods: Included in the study were 28 cases of NSCLC Lung can-
cers. We use Immunohistochemical (IHC) for VEGF protein expres-
sion. Their Tumor DNA were extracted and studied for polymorphism 
and mutations of VEGF gene, using DNA sequencing technique.
Results:
1) Lung NSCLC showed 70% (20/28) VEGF protein expression. With 
8 cases of strongly expressed and 12 cases of low expressed VEGF 
protein. DNA sequence of VEGF gene showed no mutations in 8 
cases of strongly expressed VEGF and 11 cases of low expressed 
VEGF protein. VEGF gene mutations occurred in VEGF negative at 
the rate of 3/8 and 1/12 in low expressed VEGF protein. The muta-
tion of VEGF gene in NSCLC lung cancer occurred at the rate of 
4/28 = 14 % 
2) Polymorphism study in all positive VEGF appeared to suggest that 
weakly expressed protein had genotype codon 108 AA with less 
tumor aggressiveness. And genotype codon 108G/G and/or codon 
108 G/A appeared to be associated with more aggressiveness.
3) All the NSCLC responders showed low expressed VEGF protein or 
VEGF negative protein
Conclusion:
1) Tumors with VEGF protein positive did not have any VEGF gene 
mutations.
2) It appeared that only VEGF protein negative tumors showed muta-
tions in their VEGF gene.
3) Low VEGF protein expression and No VEGF protein expression 
appeared to do well and survived longer after treatment. The level 
of VEGF protein expression and their relationship with EGFR and 
KRAS mutations in our NSCLC lung cancers will be included in our 
presentation. 
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Background: 14-3-3 proteins have 130 potential binding partners, 
including Cbl. 14-3-3 expression can prevent mutant EGFR binding to 
Cbl, impairing ubiquitination and endocytosis. 14-3-3 σ is frequently 
methylated in NSCLC; we hypothesized that in the presence of EGFR 
mutations, methylated 14-3-3 σ could permit the formation of the 
EGFR-Cbl complex. CHFR is a checkpoint that delays entry into meta-
phase in response to mitotic stress. 
Methods: 73 stage IV NSCLC p with EGFR exon 19 deletion or 
exon 21 L858R mutation received ﬁrst- or second-line erlotinib single 
therapy. 14-3-3σ and CHFR methylation was examined in the baseline 
serum of these p. 
Results: Median age, 63 (range, 26-83); females, 48 p (65.8%); Cauca-
sian, 72 p, Asian, 1 p; never-smokers, 45 p, ex-smokers, 21 p, smokers, 
7 p; adenocarcinoma, 64 p, large cell carcinoma, 9. PS: 0, 19 p, 1, 42 p, 
2-3, 12 p. 14-3-3σ was methylated in 39.7% and CHFR in 42.5% of p. 
No differences in p characteristics were observed according to methyla-
tion status. Complete response was observed in 11.1% of p, and partial 
response in 75.4%. Overall response was 86.5%. There was a trend 
toward a higher response rate in p with unmethylated CHFR (94.4% vs 
76.6%; P=ns). Overall median time to progression (TTP) and survival 
